Document is current
Any future updates will be listed below
-
Authors
Notti, Ryan Q. https://orcid.org/0000-0002-9197-6134
Yi, Fei https://orcid.org/0009-0005-9031-2116
Heissel, Søren
Bush, Martin W. https://orcid.org/0000-0002-0472-5725
Molvi, Zaki
Das, Pujita
Molina, Henrik https://orcid.org/0000-0001-8950-4990
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
Walz, Thomas https://orcid.org/0000-0003-2606-2835
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 18 November 2025
First Online: 16 December 2025
Competing interests
: C.A.K. is an inventor on patents related to TCR discovery and public neoantigen-specific TCRs and is recipient of licensing revenue shared according to MSKCC institutional policies. C.A.K. has consulted for or is on the scientific advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma, and T-knife. C.A.K. is a scientific co-founder and equity holder in Affini-T Therapeutics. The remaining authors declare no competing interests.
